JP2016531563A5 - - Google Patents

Download PDF

Info

Publication number
JP2016531563A5
JP2016531563A5 JP2016525279A JP2016525279A JP2016531563A5 JP 2016531563 A5 JP2016531563 A5 JP 2016531563A5 JP 2016525279 A JP2016525279 A JP 2016525279A JP 2016525279 A JP2016525279 A JP 2016525279A JP 2016531563 A5 JP2016531563 A5 JP 2016531563A5
Authority
JP
Japan
Prior art keywords
cancer
liver
hcc
medicament
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016525279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531563A (ja
Filing date
Publication date
Priority claimed from KR20130080579A external-priority patent/KR20150006742A/ko
Application filed filed Critical
Publication of JP2016531563A publication Critical patent/JP2016531563A/ja
Publication of JP2016531563A5 publication Critical patent/JP2016531563A5/ja
Withdrawn legal-status Critical Current

Links

JP2016525279A 2013-07-09 2014-07-09 肝臓癌関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体及びこれを含む癌予防または治療用組成物 Withdrawn JP2016531563A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130080579A KR20150006742A (ko) 2013-07-09 2013-07-09 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
KR10-2013-0080579 2013-07-09
PCT/KR2014/006145 WO2015005669A1 (en) 2013-07-09 2014-07-09 LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME

Publications (2)

Publication Number Publication Date
JP2016531563A JP2016531563A (ja) 2016-10-13
JP2016531563A5 true JP2016531563A5 (https=) 2016-12-01

Family

ID=52280271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016525279A Withdrawn JP2016531563A (ja) 2013-07-09 2014-07-09 肝臓癌関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体及びこれを含む癌予防または治療用組成物

Country Status (7)

Country Link
US (1) US20160168573A1 (https=)
EP (1) EP3019611A4 (https=)
JP (1) JP2016531563A (https=)
KR (1) KR20150006742A (https=)
CN (1) CN105765069A (https=)
SG (1) SG11201600076WA (https=)
WO (1) WO2015005669A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018306411B2 (en) 2017-07-28 2022-03-31 Lemonex Inc. Pharmaceutical composition for preventing or treating liver cancer
CN110964816A (zh) * 2019-11-20 2020-04-07 深圳市鲲鹏未来科技有限公司 包含血液稳定性纳米颗粒的溶液、其制备方法及miRNA标志物的检测方法
CN111189808B (zh) * 2019-12-25 2022-12-06 宁夏医科大学总医院 与肝脏损伤、肝细胞凋亡相关特异蛋白分子标志物筛选方法
CN111596059A (zh) * 2020-05-19 2020-08-28 上海长海医院 Gankyrin蛋白作为新型分子标志物在前列腺癌预后评估中的应用
WO2023013818A1 (ko) * 2021-08-06 2023-02-09 주식회사 네오나 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
KR102329524B1 (ko) * 2021-08-06 2021-11-23 주식회사 네오나 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
KR20250075673A (ko) * 2022-09-28 2025-05-28 오하이오 스테이트 이노베이션 파운데이션 암 전이 치료를 위한 rna 복합체 및 나노 구조
CN117281792A (zh) * 2023-07-25 2023-12-26 浙江大学 一种用于增强肝癌免疫疗法治疗效果的纳米制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE209887T1 (de) * 1993-04-02 2001-12-15 Anticancer Inc Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
AU2005292083A1 (en) * 2004-09-29 2006-04-13 Alza Corporation Microparticles and nanoparticles containing a lipopolymer
WO2008087643A2 (en) * 2007-01-16 2008-07-24 Proteologics Ltd Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
KR101224828B1 (ko) * 2009-05-14 2013-01-22 (주)바이오니아 siRNA 접합체 및 그 제조방법
JP2012503494A (ja) * 2009-11-06 2012-02-09 チュン−アン ユニバーシティ インダストリー−アカデミー コーオペレイション ファンデイション ナノ粒子を含む遺伝子運搬体
CA2859127C (en) * 2011-12-15 2017-04-25 Bioneer Corporation Novel oligonucleotide conjugates and use thereof

Similar Documents

Publication Publication Date Title
JP2016531563A5 (https=)
Giuliano et al. Mechanisms of resistance to anti-angiogenesis therapies
Khimji et al. Endothelin—biology and disease
Mahmoudi et al. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy
Laurent et al. Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles
Geszke-Moritz et al. Quantum dots as versatile probes in medical sciences: synthesis, modification and properties
JP2019526543A5 (https=)
JP2018513104A5 (https=)
EP2844736A4 (en) Modified bacteria and uses thereof for the treatment of carcinomas or tumors
NZ701575A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
BR112014027952A2 (pt) anticorpos capazes de se ligar ao fator xi de coagulação e/ou à sua forma ativada fator xia e suas utilizações.
UA114902C2 (uk) Виділене антитіло, яке зв'язує парний спіральний філамент-тау (псф-тау), та фармацевтична композиція, що містить таке антитіло
MX2015011583A (es) Derivados de amatoxina.
JP2015516989A5 (https=)
WO2014163714A3 (en) Antibody drug conjugates
CN109689641A (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
MX2013010286A (es) Conjugados de amatoxinas con enlaces mejorados.
BR112012024710A8 (pt) moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem
HK1215868A1 (zh) 双特异性构建体及其用於治疗多种疾病的用途
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
WO2015058861A8 (en) Bispecific constructs and their use in the treatment of various diseases
IL240731B (en) An antibody that binds the p19 subunit of il-23, its production process, a pharmaceutical preparation containing it and its use in cancer treatment
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
HK1252852A1 (zh) 阻止HIF2α基因表达的组合物及方法
CL2012002745A1 (es) Anticuerpos humanizados que se unen a il-25; ácido nucleico aislado que lo codifica; vector de expresión que comprende dicho ácido nucleico; célula huésped que porta dicho vector; método de producción de dicho anticuerpo; composición farmacéutica que lo comprende; y su uso para tratar o prevenir el asma, colitis ulcerativa, enfermedad de crohn o una enfermedad inflamatoria del intestino.